Regenerative Medicine for Parkinson's Disease

被引：5

作者：

Yasuhara, Takao ^{[1
]}

Kameda, Masahiro ^{[1
]}

Agari, Takashi ^{[1
]}

Date, Isao ^{[1
]}

机构：

[1] Okayama Univ, Grad Sch Med, Dept Neurol Surg, Okayama, Okayama 7008558, Japan

来源：

NEUROLOGIA MEDICO-CHIRURGICA | 2015年 / 55卷 / 02期

关键词：

cell therapy; dopaminergic neuron; gene therapy; induced pluripotent stem cells; PLURIPOTENT STEM-CELLS; GENE-THERAPY; RAT MODEL; NEUROTROPHIC FACTOR; DOPAMINERGIC-NEURONS; SUBSTANTIA-NIGRA; DOUBLE-BLIND; OPEN-LABEL; CLINICAL-APPLICATION; FUNCTIONAL-NEURONS;

D O I：

10.2176/nmc.ra.2014-0264

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Regenerative medicine for Parkinson's disease (PD) is expected to develop dramatically with the advancement of biotechnology as represented by induced pluripotent stem cells. Existing therapeutic strategy for PD consists of medication using L-DOPA, surgery such as deep brain stimulation and rehabilitation. Current treatment cannot stop the progression of the disease, although there is definite therapeutic effect. True neurorestoration is strongly desired by regenerative medicine. This review article describes the historical development of regenerative medicine for PD, with a focus on fetal nigral cell transplantation and glial cell line-derived neurotrophic factor infusion. Subsequently, the current status of regenerative medicine for PD in terms of cell therapy and gene therapy are reviewed. In the end, the future direction to realize regenerative medicine for PD is discussed.

引用

页码：113 / 123

页数：11

共 86 条

[1]

[Anonymous], NEUROREHABIL NEURAL

[2] GDNF induces recovery of the nigrostriatal dopaminergic system in the rat brain following intracerebroventricular or intraparenchymal administration [J].

Aoi, M ;

Date, I ;

Tomita, S ;

Ohmoto, T .

ACTA NEUROCHIRURGICA, 2000, 142 (07) :805-810

[3]

Azzouz M, 2002, J NEUROSCI, V22, P10302

[4] Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy [J].

Bartus, Raymond T. ;

Weinberg, Marc S. ;

Samulski, R. Jude .

MOLECULAR THERAPY, 2014, 22 (03) :487-497

[5] Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients [J].

Bartus, Raymond T. ;

Baumann, Tiffany L. ;

Siffert, Joao ;

Herzog, Christopher D. ;

Alterman, Ron ;

Boulis, Nicholas ;

Turner, Dennis A. ;

Stacy, Mark ;

Lang, Anthony E. ;

Lozano, Andres M. ;

Olanow, C. Warren .

NEUROLOGY, 2013, 80 (18) :1698-1701

[6] Parkinson's disease: A genetic perspective [J].

Belin, Andrea C. ;

Westerlund, Marie .

FEBS JOURNAL, 2008, 275 (07) :1377-1383

[7]

Benabid AL, 2000, NEUROLOGY, V55, pS40

[8]

Borlongan CV, 1999, LANCET, V353, pSL29

[9] Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling [J].

Chambers, Stuart M. ;

Fasano, Christopher A. ;

Papapetrou, Eirini P. ;

Tomishima, Mark ;

Sadelain, Michel ;

Studer, Lorenz .

NATURE BIOTECHNOLOGY, 2009, 27 (03) :275-280

[10] Neural transplantation and trophic factors in Parkinson's disease: Special reference to chromaffin cell grafting, NGF support from pretransected peripheral nerve, and encapsulated dopamine-secreting cell grafting [J].

Date, I ;

Ohmoto, T .

EXPERIMENTAL NEUROLOGY, 1996, 137 (02) :333-344

← 1 2 3 4 5 6 7 8 9 →